COPD in the Elderly Patient

ABSTRACT

The elderly are especially prone to the adverse health effects of chronic obstructive pulmonary disease (COPD), which is a common disorder in that population. While the prevalence and morbidity of COPD in the elderly are high, it is often undiagnosed and thus undertreated. The diagnosis of COPD is primarily based on the physiological documentation of airflow limitation using spirometry. However, several controversies exist as to the range of predicted normal values for these measurements in the elderly population, and the clinical presentation of COPD in the elderly may be complicated by the presence of several comorbidities. Many nonpharmcological and pharmacological interventions are available for managing COPD. However, management of COPD in the elderly population may be challenged by the “polypharmacy” of medications that these patients often take, which can interfere with compliance with therapy. Additionally, the elderly often suffer from physical or cognitive disabilities that can prevent compliance with prescribed medications. Lastly, adverse effects from medications prescribed for treatment of COPD may be more pervasive in elderly patients.

KEYWORDS

Aging - emphysema - chronic bronchitis - COPD

REFERENCES

• 1 NCHS-FASTSTAT (CDC) .Chronic Obstructive Pulmonary Disease (COPD). 2005:3-1-2009 Available at: http://www.cdc.gov/nchs/fastats/copd.htm
• 2 Rennard S I, Vestbo J. COPD: the dangerous underestimate of 15%.  Lancet. 2006;  367 1216-1219
• 3 World Health Organization .Statistical Dataset. Geneva, Switzerland; World Health Organization 2000 3-1-2009 Available at: http://www.who.int/respiratory/copd/burden/en/index.html
• 4 Halbert R J, Natoli J L, Gano A, Badamgarav E, Buist A S, Mannino D M. Global burden of COPD: systematic review and meta-analysis.  Eur Respir J. 2006;  28 523-532
• 5 Buist A S, McBurnie M A, Vollmer W M BOLD Collaborative Research Group et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study.  Lancet. 2007;  370 741-750
• 6 Foster T S, Miller J D, Marton J P, Caloyeras J P, Russell M W, Menzin J. Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature.  COPD. 2006;  3 211-218
• 7 Mannino D M. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity.  Chest. 2002;  121(5, Suppl) 121S-126S
• 8 Menzin J, Boulanger L, Marton J et al.. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.  Respir Med. 2008;  102 1248-1256
• 9 Knudson R J. Physiology of the aging lung. In: Crystal RG, West JB The Lung: Scientific Foundations. New York; Raven 1991: 1749-1760
• 10 de Bisschop C, Marty M L, Tessier J F, Barberger-Gateau P, Dartigues J F, Guénard H. Expiratory flow limitation and obstruction in the elderly.  Eur Respir J. 2005;  26 594-601
• 11 Pride N B. Ageing and changes in lung mechanics.  Eur Respir J. 2005;  26 563-565
• 12 Mahler D A, Rosiello R A, Loke J. The aging lung.  Clin Geriatr Med. 1986;  2 215-225
• 13 Black L F, Hyatt R E. Maximal respiratory pressures: normal values and relationship to age and sex.  Am Rev Respir Dis. 1969;  99 696-702
• 14 Svartengren M, Falk R, Philipson K. Long-term clearance from small airways decreases with age.  Eur Respir J. 2005;  26 609-615
• 15 Behrendt C E. Mild and moderate-to-severe COPD in nonsmokers: distinct demographic profiles.  Chest. 2005;  128 1239-1244
• 16 Zhou Y, Wang C, Yao W et al.. COPD in Chinese nonsmokers.  Eur Respir J. 2009;  33 509-518
• 17 Ito K, Barnes P J. COPD as a disease of accelerated lung aging.  Chest. 2009;  135 173-180
• 18 Sharma G, Hanania N A, Shim Y M. The aging immune system and its relationship to the development of chronic obstructive pulmonary disease.  Proc Am Thorac Soc. 2009;  6 573-580
• 19 Barnes P J. Future treatments for chronic obstructive pulmonary disease and its comorbidities.  Proc Am Thorac Soc. 2008;  5 857-864
• 20 Vallejo A N. Age-dependent alterations of the T cell repertoire and functional diversity of T cells of the aged.  Immunol Res. 2006;  36 221-228
• 21 Cosio M G, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease.  N Engl J Med. 2009;  360 2445-2454
• 22 Engström G, Segelstorm N, Ekberg-Aronsson M, Nilsson P M, Lindgärde F, Löfdahl C G. Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study.  Thorax. 2009;  64 211-215
• 23 Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease.  Respir Med. 2009;  103 1231-1238
• 24 Hardie J A, Vollmer W M, Buist A S, Bakke P, Mørkve O. Respiratory symptoms and obstructive pulmonary disease in a population aged over 70 years.  Respir Med. 2005;  99 186-195
• 25 Hardie J A, Buist A S, Vollmer W M, Ellingsen I, Bakke P S, Mørkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers.  Eur Respir J. 2002;  20 1117-1122
• 26 Bhatt N Y, Wood K L. What defines abnormal lung function in older adults with chronic obstructive pulmonary disease?.  Drugs Aging. 2008;  25 717-728
• 27 Medbø A, Melbye H. Lung function testing in the elderly—can we still use FEV1/FVC< 70% as a criterion of COPD?.  Respir Med. 2007;  101 1097-1105
• 28 Mannino D M, Sonia Buist A, Vollmer W M. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?.  Thorax. 2007;  62 237-241
• 29 Melbye H, Medbø A, Crockett A. The FEV1/FEV6 ratio is a good substitute for the FEV1/FVC ratio in the elderly.  Prim Care Respir J. 2006;  15 294-298
• 30 Sin B A, Akkoca O, Saryal S, Oner F, Misirligil Z. Differences between asthma and COPD in the elderly.  J Investig Allergol Clin Immunol. 2006;  16 44-50
• 31 Hardie J A, Vollmer W M, Buist A S, Ellingsen I, Mørkve O. Reference values for arterial blood gases in the elderly.  Chest. 2004;  125 2053-2060
• 32 Celli B R, Cote C G, Marin J M et al.. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.  N Engl J Med. 2004;  350 1005-1012
• 33 Agustí A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should).  Proc Am Thorac Soc. 2007;  4 522-525
• 34 Celli B R, MacNee W. ATS/ERS Task Force . Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.  Eur Respir J. 2004;  23 932-946
• 35 Murphy T F, Sethi S. Chronic obstructive pulmonary disease: role of bacteria and guide to antibacterial selection in the older patient.  Drugs Aging. 2002;  19 761-775
• 36 Fiore M C. AHCPR smoking cessation guideline: a fundamental review.  Tob Control. 1997;  6(Suppl 1) S4-S8
• 37 Bellia V, Battaglia S, Matera M G, Cazzola M. The use of bronchodilators in the treatment of airway obstruction in elderly patients.  Pulm Pharmacol Ther. 2006;  19 311-319
• 38 Ohta K, Fukuchi Y, Grouse L et al.. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD.  Respir Med. 2004;  98 1016-1024
• 39 Jarvis S, Ind P W, Shiner R J. Inhaled therapy in elderly COPD patients; time for re-evaluation?.  Age Ageing. 2007;  36 213-218
• 40 Naunheim K S, Wood D E, Krasna M J National Emphysema Treatment Trial Research Group et al. Predictors of operative mortality and cardiopulmonary morbidity in the National Emphysema Treatment Trial.  J Thorac Cardiovasc Surg. 2006;  131 43-53
• 41 Kaiwa Y, Kurokawa Y. Lung volume reduction surgery for chronic pulmonary emphysema in elderly patients [in Japanese].  Kyobu Geka. 2005;  58(8, Suppl) 709-713
• 42 Fukuse T, Satoda N, Hijiya K, Fujinaga T. Importance of a comprehensive geriatric assessment in prediction of complications following thoracic surgery in elderly patients.  Chest. 2005;  127 886-891
• 43 Incalzi R A, Corsonello A, Pedone C et al.. Use of antibiotics in elderly patients with exacerbated COPD: the OLD-chronic obstructive pulmonary disease study.  J Am Geriatr Soc. 2006;  54 642-647
• 44 Au D H, Udris E M, Fihn S D, McDonell M B, Curtis J R. Differences in health care utilization at the end of life among patients with chronic obstructive pulmonary disease and patients with lung cancer.  Arch Intern Med. 2006;  166 326-331
• 45 Claessens M T, Lynn J, Zhong Z Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments et al. Dying with lung cancer or chronic obstructive pulmonary disease: insights from SUPPORT.  J Am Geriatr Soc. 2000;  48(5, Suppl) S146-S153
• 46 Hansen-Flaschen J. Chronic obstructive pulmonary disease: the last year of life.  Respir Care. 2004;  49 90-97 discussion 97-98
• 47 Curtis J R, Engelberg R A, Nielsen E L, Au D H, Patrick D L. Patient-physician communication about end-of-life care for patients with severe COPD.  Eur Respir J. 2004;  24 200-205
• 48 Heffner J E, Fahy B, Hilling L, Barbieri C. Outcomes of advance directive education of pulmonary rehabilitation patients.  Am J Respir Crit Care Med. 1997;  155 1055-1059
• 49 Stapleton R D, Nielsen E L, Engelberg R A, Patrick D L, Curtis J R. Association of depression and life-sustaining treatment preferences in patients with COPD.  Chest. 2005;  127 328-334
• 50 Curtis J R, Wenrich M D, Carline J D, Shannon S E, Ambrozy D M, Ramsey P G. Patients' perspectives on physician skill in end-of-life care: differences between patients with COPD, cancer, and AIDS.  Chest. 2002;  122 356-362
• 51 McNeely P D, Hébert P C, Dales R E et al.. Deciding about mechanical ventilation in end-stage chronic obstructive pulmonary disease: how respirologists perceive their role.  CMAJ. 1997;  156 177-183
• 52 Murray S A, Kendall M, Boyd K, Sheikh A. Illness trajectories and palliative care.  BMJ. 2005;  330 1007-1011
• 53 Curtis J R, Cook D J, Sinuff T Society of Critical Care Medicine Palliative Noninvasive Positive Ventilation Task Force et al. Noninvasive positive pressure ventilation in critical and palliative care settings: understanding the goals of therapy.  Crit Care Med. 2007;  35 932-939